Literature DB >> 19914299

Fluoxetine improves the memory deficits caused by the chemotherapy agent 5-fluorouracil.

Maha ElBeltagy1, Sarah Mustafa, Jariya Umka, Laura Lyons, Ahmed Salman, Gloria Tu Chur-yoe, Nikita Bhalla, Geoffrey Bennett, Peter M Wigmore.   

Abstract

Cancer patients who have been treated with systemic adjuvant chemotherapy have described experiencing deteriorations in cognition. A widely used chemotherapeutic agent, 5-fluorouracil (5-FU), readily crosses the blood-brain barrier and so could have a direct effect on brain function. In particular this anti mitotic drug could reduce cell proliferation in the neurogenic regions of the adult brain. In contrast reports indicate that hippocampal dependent neurogenesis and cognition are enhanced by the SSRI antidepressant Fluoxetine. In this investigation the behavioural effects of chronic (two week) treatment with 5-FU and (three weeks) with Fluoxetine either separately or in combination with 5-FU were tested on adult Lister hooded rats. Behavioural effects were tested using a context dependent conditioned emotional response test (CER) which showed that animals treated with 5-FU had a significant reduction in freezing time compared to controls. A separate group of animals was tested using a hippocampal dependent spatial working memory test, the object location recognition test (OLR). Animals treated only with 5-FU showed significant deficits in their ability to carry out the OLR task but co administration of Fluoxetine improved their performance. 5-FU chemotherapy caused a significant reduction in the number of proliferating cells in the sub granular zone of the dentate gyrus compared to controls. This reduction was eliminated when Fluoxetine was co administered with 5-FU. Fluoxetine on its own had no effect on proliferating cell number or behaviour. These findings suggest that 5-FU can negatively affect both cell proliferation and hippocampal dependent working memory and that these deficits can be reversed by the simultaneous administration of the antidepressant Fluoxetine. Copyright 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19914299     DOI: 10.1016/j.bbr.2009.11.017

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  36 in total

1.  Chronic fluoxetine ameliorates adolescent chronic nicotine exposure-induced long-term adult deficits in trace conditioning.

Authors:  David A Connor; Thomas J Gould
Journal:  Neuropharmacology       Date:  2017-08-02       Impact factor: 5.250

2.  Influence of nicotine on doxorubicin and cyclophosphamide combination treatment-induced spatial cognitive impairment and anxiety-like behavior in rats.

Authors:  Yoshihisa Kitamura; Erika Kanemoto; Misaki Sugimoto; Ayumi Machida; Yuka Nakamura; Nanami Naito; Hirotaka Kanzaki; Ikuko Miyazaki; Masato Asanuma; Toshiaki Sendo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-01-07       Impact factor: 3.000

Review 3.  Brain vulnerability to chemotherapy toxicities.

Authors:  Tim A Ahles
Journal:  Psychooncology       Date:  2012-10-01       Impact factor: 3.894

4.  Effects of repeated administration of chemotherapeutic agents tamoxifen, methotrexate, and 5-fluorouracil on the acquisition and retention of a learned response in mice.

Authors:  Ellen A Walker; John J Foley; Rachel Clark-Vetri; Robert B Raffa
Journal:  Psychopharmacology (Berl)       Date:  2011-05-03       Impact factor: 4.530

5.  Cognitive impairments caused by oxaliplatin and 5-fluorouracil chemotherapy are ameliorated by physical activity.

Authors:  Joanna E Fardell; Janette Vardy; Jeanette D Shah; Ian N Johnston
Journal:  Psychopharmacology (Berl)       Date:  2011-09-06       Impact factor: 4.530

6.  Chemotherapy disrupts learning, neurogenesis and theta activity in the adult brain.

Authors:  Miriam S Nokia; Megan L Anderson; Tracey J Shors
Journal:  Eur J Neurosci       Date:  2012-10-08       Impact factor: 3.386

Review 7.  Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults.

Authors:  Jeffrey S Wefel; Shelli R Kesler; Kyle R Noll; Sanne B Schagen
Journal:  CA Cancer J Clin       Date:  2014-12-05       Impact factor: 508.702

8.  Cognitive impact of cytotoxic agents in mice.

Authors:  R Seigers; M Loos; O Van Tellingen; W Boogerd; A B Smit; S B Schagen
Journal:  Psychopharmacology (Berl)       Date:  2014-06-04       Impact factor: 4.530

Review 9.  Consequences of cancer treatments on adult hippocampal neurogenesis: implications for cognitive function and depressive symptoms.

Authors:  Gisele Pereira Dias; Ronan Hollywood; Mário Cesar do Nascimento Bevilaqua; Anna Claudia Domingos da Silveira da Luz; Robert Hindges; Antonio Egidio Nardi; Sandrine Thuret
Journal:  Neuro Oncol       Date:  2014-01-26       Impact factor: 12.300

Review 10.  Cancer- and cancer treatment-associated cognitive change: an update on the state of the science.

Authors:  Tim A Ahles; James C Root; Elizabeth L Ryan
Journal:  J Clin Oncol       Date:  2012-09-24       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.